Nasal Nitric Oxide Levels in HIV Infection: A Cross-Sectional Study
Table 1
Characteristics of study participants.
Characteristics or outcome
HIV+ with suppressed VL on ART ()
HIV+ with detectable VL off ART ()
Healthy controls ()
Age, years [mean (std)]#
48 (10)
45 (9)
43 (12)
0.327
Male sex [
28 (68%)
3 (60%)
5 (42%)
0.297
Duration of HIV infection, years [mean (std)]~
16 (9)
10 (8)
- -
0.209
Antiretroviral regimen [number (%)]1; NRTIs and
PI
11 (27%)
NA
NA
NA
NNRTI
10 (24%)
Integrase inhibitor
27 (66%)
Cell-entry inhibitor
1 (2%)
Duration of viral load suppression, years [mean (std)]
6 (3)
NA
NA
NA
Duration of detectable viral load years [mean (std)]
NA
3 (3)
NA
NA
CD4 count (cells/μl)
All patients [mean (std)]~
543 (301)
496 (195)
- -
0.737
Patients with CD4 ≤350
16 (39%)
1 (20%)
0.674
Patients with CD4 351–499 [ (%)]
5 (12%)
1 (20%)
Patients with CD4 ≥500 [ (%)]
20 (49%)
3 (60%)
CD4% [mean (std)]~
31 (12)
25 (6%)
0.256
CD8 count (cells/μl), [mean (std)]~
809 (452)
1041 (331)
0.275
CD4/CD8 ratio [mean (std)]~
0.817 (0.509)
052 (0.278)
0.210
Nadir CD4 count (cells/μl) [mean (std)]
203 (147)
280 (166)
- -
0.329
Viral load, VL; standard deviation, std; nucleoside reverse transcriptase inhibitor, NRTI; protease inhibitor, PI; nonnucleoside reverse transcriptase inhibitor, NNRTI; integrase inhibitor, II; not applicable, NA; surpass 100% as some individuals were on more than 1 drug class in addition to a NRTI backbone; statistical tests used for comparison: #ANOVA; ’s exact test; ~independent sample -test.
